What do systematic reviews say?

Intervention not reported

• The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 997 participants
  High

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

Flutamide 250 mg once to b.i.d. showed no clear difference in participant‐reported improvement of hirsutism 4‐point Likert scale compared with spironolactone 100 mg (low certainty).

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  RR 2 [0.88, 4.54]
  1 study · 20 participants
  Low

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 40 participants
  Low

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 40 participants
  Very low

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 40 participants
  Moderate

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Finasteride 5 mg vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 34 participants
  Low

Finasteride 5 mg vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Finasteride 5 mg vs spironolactone 100 mg

Finasteride 5 mg showed no clear difference in proportion of participants who reported an adverse event compared with spironolactone 100 mg (moderate certainty).

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  RR 0.2 [0.03, 1.41]
  1 study · 20 participants
  Moderate

Finasteride 5 mg vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 34 participants
  Low

Finasteride 5 mg vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 34 participants
  Low

Finasteride 5 mg vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Finasteride 5 mg vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Deferasirox vs deferiprone (DFO)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Deferasirox vs deferiprone (DFO)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  1.54 [0.44, 5.39]
  1 study · 390 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

It is very uncertain whether summary of findings: Comparison 3 ‐ deferiprone (DFP) changes total SAEs compared with deferasirox (DFX) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.95 [0.46, 1.96]
  1 study · 390 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

Summary of findings: Comparison 3 ‐ deferiprone (DFP) showed no clear difference in all‐cause mortality (n/N) compared with deferasirox (DFX) (low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RD 0
  1 study · 390 participants
  Low